drugset / Trial / NCT06176027
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Phase 1/2
Recruiting
52 enrolled
Navy General Hospital, Beijing
Chinese PLA General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with CAOLD Regimen in the treatment of relapsed/refractory peripheral t-cell lymphomas.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2028-09-01
- Completion
- 2030-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 400 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 30 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 7.5 mg/m2 | — |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 iu | — |
| Subject | Vindesine | Small molecule | 2 mg/m2 | — |